Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ELANE | P08246 | 4/20 | 0.43 |
| ▸ | CMA1 | P23946 | 14/20 | 0.42 |
| ▸ | CTRC | Q99895 | 2/20 | 0.42 |
| ▸ | TP53 | P04637 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12513720 | 0.91 | CMA1 (0.42) | ELANECMA1CTRCTP53 | |
| SCHEMBL14174418 | 0.88 | TP53 (0.44) | ELANECMA1CTRCTP53 | |
| SCHEMBL3832817 | 0.86 | TRPV1 (0.40) | ELANECMA1CTRC | |
| SCHEMBL2211805 | 0.85 | ELANE (0.58) | ELANECMA1 | |
| SCHEMBL2209970 | 0.83 | F7 (0.49) | ELANETP53 | |
| SCHEMBL2209964 | 0.83 | F7 (0.49) | ELANETP53 | |
| SCHEMBL2209218 | 0.82 | TP53 (0.39) | ELANECMA1TP53 | |
| SCHEMBL2209223 | 0.82 | TP53 (0.39) | ELANECMA1TP53 | |
| SCHEMBL3832813 | 0.80 | CA12 (0.38) | ELANETP53 | |
| SCHEMBL2213960 | 0.80 | CMA1 (0.46) | ELANECMA1CTRC |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8048886-B2 | Substituted pyrazine-3-one-derivatives as IAP inhibitors | NOVARTIS AG (CH) | 2011-11-01 | — | — | US | claimed |
| EP-2099769-B1 | 6-OXO.-1, 6-DIHYDROPYRIMIDIN-2-YLS IN THE TREATMENT OF PROLIFERATIVE DISEASES | NOVARTIS AG (CH) | 2011-07-27 | — | — | EP | claimed |
| US-20100249405-A1 | Organic Compounds | NOVARTIS AG | 2010-09-30 | — | — | US | claimed |
| US-20110319614-A1 | Organic Compounds | NOVARTIS AG (CH) | 2011-12-29 | — | — | US | disclosed |
| US-20110319614-A1 | Organic Compounds | NOVARTIS AG (CH) | 2011-12-29 | — | — | US | disclosed |
| US-8048886-B2 | Substituted pyrazine-3-one-derivatives as IAP inhibitors | NOVARTIS AG (CH) | 2011-11-01 | — | — | US | disclosed |
| US-8048886-B2 | Substituted pyrazine-3-one-derivatives as IAP inhibitors | NOVARTIS AG (CH) | 2011-11-01 | — | — | US | disclosed |
| EP-2099769-B1 | 6-OXO.-1, 6-DIHYDROPYRIMIDIN-2-YLS IN THE TREATMENT OF PROLIFERATIVE DISEASES | NOVARTIS AG (CH) | 2011-07-27 | — | — | EP | disclosed |
| US-20100249405-A1 | Organic Compounds | NOVARTIS AG | 2010-09-30 | — | — | US | disclosed |
| US-20100249405-A1 | Organic Compounds | NOVARTIS AG | 2010-09-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110319614-A1 | Organic Compounds | XIAP, BIRC5, BIRC3 | ELANE 592/4885CMA1 852/4885CTRC 2753/4885 |
| US-20100249405-A1 | Organic Compounds | XIAP, BIRC5, BIRC3 | ELANE 592/4885CMA1 852/4885CTRC 2753/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.